Patents Issued in June 12, 2018
  • Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced Ostwald ripening
    Patent number: 9993454
    Abstract: The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances such as docetaxel with reduced Ostwald ripening.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: June 12, 2018
    Assignee: Luminus Biosciences, Inc.
    Inventor: Chandra Ulagaraj Singh
  • Method of mitigating long term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
    Patent number: 9993455
    Abstract: Mitigation of long term detrimental effects of exposure to medical imaging ionizing radiation by administration of an amount of genistein in the form of a nanosuspension to someone effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to medical imaging ionizing radiation to twelve hours after exposure to medical imaging ionizing radiation.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: June 12, 2018
    Assignee: Humanetics Corporation
    Inventors: Michael D. Kaytor, John L. Zenk
  • Preparation and use of a composition for prevention and mitigation of the effects of radiation
    Patent number: 9993456
    Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: June 12, 2018
    Assignees: The Board of Trustees of the University of Arkansas, Universidad Tecnica Particular De Loja, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen, Raul G. Enriquez, Sujay Kharade, Omar Malagon, Yadira Ordonez, Edgar Ojeda, Shraddha Thakkar, E. Nathalie Pineda, Darin Jones
  • Method of improving visual processing, visual acuity, or both by administering compositions comprising RRR-alpha-tocopherol and carotenoid to infants
    Patent number: 9993457
    Abstract: Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are also disclosed. Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 12, 2018
    Assignee: Abbott Laboratories
    Inventors: Matthew Kuchan, Chron-Si Lai, Jacqueline Boff
  • Method of treating MYC-amplified tumors with RNA-polymerase II inhibitors
    Patent number: 9993458
    Abstract: Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: June 12, 2018
    Assignees: Institute For Cancer Research, NexusPharma, Inc.
    Inventors: Igor Astsaturov, Vladimir Khazak, Ilya Serebriiski
  • Selective HDAC6 inhibitors and uses thereof
    Patent number: 9993459
    Abstract: The present invention relates to selective Histone deacetylase 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferative disease, an autoimmune or inflammatory disorder, a neurodegenerative disease, or a combination thereof, also are disclosed.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: June 12, 2018
    Assignee: Universiteit Gent
    Inventors: Rob De Vreese, Matthias D'Hooghe
  • Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
    Patent number: 9993460
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 12, 2018
    Assignee: RACE ONCOLOGY LTD.
    Inventors: William J. Garner, Amie Franklin, John Rothman
  • Method for treating disorders associated with glomerular function
    Patent number: 9993461
    Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 12, 2018
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
  • Hydantoin derivative-containing pharmaceutical composition
    Patent number: 9993462
    Abstract: The present invention provides pharmaceutical compositions for inducing bone and/or cartilage anabolism, which comprises as an active ingredient a compound represented by formula (1) below and a pharmacologically acceptable salt thereof: wherein R1, R2, R3, and R4 are as defined in the claims.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: June 12, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Noda, Hidetomo Kitamura, Tatsuya Tamura
  • Use of maleimide derivatives for preventing and treating cancer
    Patent number: 9993463
    Abstract: The present invention is related to a compound of formula (I) a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: June 12, 2018
    Assignee: Centogene AG
    Inventors: Matthias Beller, Jan Lukas, Moritz Frech, Christian Junghanss, Arndt Rolfs, Anahit Pews-Davtyan
  • Otamixaban formulations with improved stability
    Patent number: 9993464
    Abstract: The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: June 12, 2018
    Assignee: SANOFI
    Inventors: Walter Kamm, Till Bussemer, Doris Andert, Bernd Kuehn, Ernst-Josef Todt
  • 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
    Patent number: 9993465
    Abstract: Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: June 12, 2018
    Assignees: Georgetown University, Duke University
    Inventors: Yingxian Xiao, Kenneth J. Kellar, Milton L. Brown, Mikell A. Paige, Yong Liu, Edward D. Levin, Amir H. Rezvani
  • Donepezil transdermal delivery system
    Patent number: 9993466
    Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: June 12, 2018
    Assignee: Corium International, Inc.
    Inventors: Eun Soo Lee, Amit K. Jain, Parminder Singh
  • Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
    Patent number: 9993467
    Abstract: Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: June 12, 2018
    Assignee: Celgene Corporation
    Inventors: Anthony J. Tutino, Michael T. Kelly
  • Pharmaceutical composition for topical application
    Patent number: 9993468
    Abstract: A pharmaceutical composition comprises a solution having a pH of from 5 to 7.5, including loratadine and/or desloratadine. The composition is suitable for treatment of e.g. allergic rhinitis and allergic conjunctivitis.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: June 12, 2018
    Assignee: MOURAD MANKARIOS
    Inventor: Todor Alexandrov Popov
  • Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
    Patent number: 9993469
    Abstract: The present invention provides a combination of at least one oxazolidinone-quinolone hybrid with at least one further antibacterial compound and the use thereof as drug, especially for the treatment or prophylaxis of bacterial infections.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 12, 2018
    Assignee: Morphochem Aktiengesellschaft Für Kombinatorishe Chemie
    Inventors: Thomas Kapsner, Axel Dalhoff
  • Combination therapy
    Patent number: 9993470
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: June 12, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Ophthalmic formulations of cetirizine and methods of use
    Patent number: 9993471
    Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 12, 2018
    Assignee: NICOX OPHTHALMICS, INC.
    Inventors: Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
  • Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
    Patent number: 9993472
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: June 12, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHN HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
  • Crystalline forms of tyrosine kinase inhibitors and their salts
    Patent number: 9993473
    Abstract: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 12, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Bromocriptine formulations
    Patent number: 9993474
    Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 12, 2018
    Assignee: VeroScience LLC
    Inventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
  • Method for treating a pulmonary hypertension condition
    Patent number: 9993475
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: June 12, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Substituted 5-flouro-1H-pyrazolopyridines and their use
    Patent number: 9993476
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 12, 2018
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • Substituted imidazo[1,5-a]pyrazines as PDE9 inhibitors
    Patent number: 9993477
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: June 12, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
    Patent number: 9993478
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 12, 2018
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • Trk-inhibiting compound
    Patent number: 9993479
    Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: June 12, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Kazuya Hashimura, Masahiro Ikura, Masato Higashino, Tetsuya Yasuhiro, Takeshi Nagaura
  • mTOR/JAK inhibitor combination therapy
    Patent number: 9993480
    Abstract: Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including myeloproliferative neoplasms. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: June 12, 2018
    Assignees: NOVARTIS PHARMA AG, INCYTE CORPORATION
    Inventors: Alessandro M. Vannucchi, Costanza Bogani, Paola Guglielmelli
  • Methods and compositions for the treatment of metabolic disorders
    Patent number: 9993481
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: June 12, 2018
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancer
    Patent number: 9993482
    Abstract: The present invention is directed to a combination comprising a class III receptor tyrosine kinase inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 12, 2018
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventor: Thomas Jorg Mehrling
  • Compositions and methods for treating ophthalmic, octic, or nasal infections
    Patent number: 9993483
    Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: June 12, 2018
    Assignee: Alcon Research, Ltd.
    Inventors: David W. Stroman, Masood A. Chowhan, Kenneth C. Appell
  • 2-(morpholin-4-yl)-1,7-naphthyridines
    Patent number: 9993484
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: June 12, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
  • Highly concentrated stable meloxicam solutions for needleless injection
    Patent number: 9993485
    Abstract: An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: June 12, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Martin A. Folger, Stefan Henke, Bernhard Hassel, Bernd Zierenberg
  • Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
    Patent number: 9993486
    Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: June 12, 2018
    Assignee: TLC THERAPEUTICS, LLC
    Inventors: Carl Tierney, Andrew Gardner, Jan Pick-Katolik, Stacey Powell, Mark Foley, Laurence Ramsey, Andrew Hardeman
  • Cyclodextrin and budesonide derivative compositions and methods
    Patent number: 9993487
    Abstract: The present invention relates to novel and useful pharmaceutical compositions formulated with a cyclodextrin compound and a budesonide derivative for the treatment and/or prevention of pulmonary inflammatory disease. The present invention also relates to a novel and useful analytical technique for the detection and the quantification of HP-?-CD in solution. More specifically, the present invention relates to the use of a validated 1H NMR analysis for the detection and quantification of cyclodextrins directly in pharmaceutical formulations without any extraction or separation steps for liquid formulations.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: June 12, 2018
    Inventors: Didier Cataldo, Brigitte Evrard, Gilles Dufour, Pascal de Tullio, Paul Maes
  • Dry powder formulations for inhalation
    Patent number: 9993488
    Abstract: A respirable dry powder including acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 12, 2018
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • Methods for treating solid tumor cancers using a histone deacetylase inhibitor and an I?B kinase inhibitor
    Patent number: 9993489
    Abstract: Methods for the treatment of solid tumor cancers, specifically ovarian cancer and drug-resistant solid tumors, are disclosed. A method comprises administering a combination therapy including a therapeutically effective amount of an HDAC inhibitor and a therapeutically effective amount of an IKK inhibitor to a subject in need thereof. Pharmaceutical compositions and kits comprising an HDAC inhibitor and an IKK inhibitor are also disclosed.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: June 12, 2018
    Assignee: St. John's University
    Inventors: Ivana Vancurova, Himavanth R. Gatla, Bipradeb Singha
  • Phosphonic acid compounds and screening method
    Patent number: 9993490
    Abstract: The present invention relates to pharmaceutical compositions comprising a phosphonic acid compound, such as a natural product. Such compounds can include, such as an antibiotic or compound with other activity, derived from an Actinobacteria strain having a gene encoding pepM (phosphoenolpyruvate phosphomutase) or a pepM-dependent biosynthetic pathway. The present invention also relates to methods for treating or preventing or reducing the risk of a bacterial infection by administering a therapeutically effective or prophylactically effective amount of a phosphonic acid antibiotic, or a pharmaceutical composition containing such an antibiotic, to a patient or subject in need thereof. The present invention further relates to methods for isolating, purfying, and identifying such phosphonic acid compounds from Actinobacteria strains.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 12, 2018
    Assignee: The Board of Trustees of The University of Illinois
    Inventors: William W. Metcalf, Kou-San Ju, Jiangtao Gao, James R. Doroghazi, Wilfred A. van der Donk
  • Guanine riboswitch binding compounds and their use as antibiotics
    Patent number: 9993491
    Abstract: The present invention includes novel compounds and pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against microorganisms bearing a guanine riboswitch that controls the expression of the guaA gene, including organisms which are resistant to certain antibiotic families, and which are useful as antibacterial agents for treatment or prophylaxis of bacterial infections in animals or in humans, in particular but not limited to infections of the mammary gland, or their use as antiseptics, agents for sterilization or disinfection.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 12, 2018
    Assignee: SOCPRA—SCIENCES ET GÉNIE S.E.C.
    Inventors: Jerome Mulhbacher, Daniel Lafontaine, Francois Malouin, Marianne Allard, Eric Marsault
  • Lysophospholipids and lysophospholipid analogues against honeybee brood diseases
    Patent number: 9993492
    Abstract: The present invention refers to a compound selected from the group consisting of a lysophospholipid and a lysophospholipid analog for use in the treatment or prophylaxis of honeybee brood diseases, in particular American foulbrood and European foulbrood. The invention also refers to a diet composition, a sprayable composition, a dipping solution for brood combs, a beeswax composition and liposomal and microsphere- or nanosphere-based compositions, comprising a compound according to the invention, for use in the treatment or prophylaxis of bee brood diseases.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: June 12, 2018
    Assignee: University of Graz
    Inventors: Wolfgang Schühly, Ulrike Riessberger-Gallé, Javier Hernández-López, Karl Crailsheim
  • Composition for prevention, amelioration or treatment of metabolic syndrome
    Patent number: 9993493
    Abstract: A composition comprising (a) and (b), and a food or drink or a medicine comprising the composition, wherein (a) is at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and (b) is at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5), are useful for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: June 12, 2018
    Assignee: HOUSE WELLNESS FOODS CORPORATION
    Inventors: Tatsuya Ohara, Koutarou Muroyama, Shinji Murosaki, Yoshihiro Yamamoto
  • Compositions and methods for treating fibrotic disease
    Patent number: 9993494
    Abstract: The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.
    Type: Grant
    Filed: February 7, 2015
    Date of Patent: June 12, 2018
    Assignee: eFFECTOR Therapeutics, Inc.
    Inventors: James Appleman, Peggy A. Thompson
  • Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
    Patent number: 9993495
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: June 12, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Robert L. Coffman
  • Method of administering hyaluronan formulation for supporting joint health
    Patent number: 9993496
    Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: June 12, 2018
    Assignee: Reyn Pharma, LLC
    Inventor: James D. Smith, Jr.
  • Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
    Patent number: 9993497
    Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: June 12, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'acov
  • Method for the prevention and treatment of gastrointestinal distress in horses and other species
    Patent number: 9993498
    Abstract: Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals are disclosed. The supplement comprises mastic gum and lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal with the supplement at least one daily.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 12, 2018
    Assignee: Kaeco Group, Inc.
    Inventors: Kelly Terry, Leon Kratochvil, James Harless, Tom Kratochvil
  • Product for and method of protecting and increasing friction of animal paws
    Patent number: 9993499
    Abstract: An adhesive and solid particulates adhered to the pads of an animal's paw, the adhesive being cured, thereby increasing the friction of the surface of the pads; and a method of increasing the friction of an animal's paw by applying to clean, dry pads of the animal's paw a layer of uncured adhesive, and while the adhesive layer is uncured, contacting the paw with particulates to adhere the particulates to the pad, then curing the adhesive.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: June 12, 2018
    Inventors: Stacey Bone, Jeffrey L. Harms
  • Proton-binding polymers for oral administration
    Patent number: 9993500
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: June 12, 2018
    Assignee: TRICIDA, INC.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9993501
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9993502
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Methods for production of platelets from pluripotent stem cells and compositions thereof
    Patent number: 9993503
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: June 12, 2018
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza